Veru is trading 5.1% up at $2.37 after announcing it has completed and exceeded enrollment for its Phase 2b PLATEAU trial of oral enobosarm plus semaglutide in obese patients aged 65 and older.
- The trial evaluates the combination therapy's ability to preserve muscle mass while reducing fat in the elderly population.
- This milestone in the late-stage obesity program is significantly lifting investor sentiment around the stock.
- Broader strength across the biotech sector is providing an additional tailwind for shares today.